Dietary interventions in prostate cancer

被引：6

作者：

Demark-Wahnefried W. ^{[1
]}

机构：

[1] Division of Cancer Prevention and Population Sciences, MD Anderson Cancer Center, University of Texas, Houston, TX 77030

来源：

Current Urology Reports | 2008年 / 9卷 / 3期

关键词：

Prostate Cancer; Selenium; Lycopene; Silymarin; Prostate Cancer Risk;

D O I：

10.1007/s11934-008-0038-8

中图分类号：

学科分类号：

摘要：

Our understanding of the relationship between diet and prostate cancer is still developing. Currently, randomized, controlled trials are under way that will yield evidence on which to base recommendations regarding dietary regimens, functional foods, and supplement use. For now, data mostly derive from epidemiologic investigations with limited ability to demonstrate cause and effect, or from benchtop research that may have limited application to in vivo systems, especially in humans. Insufficient evidence currently exists to support the use of specific dietary supplements or functional food. Clinicians striving for best clinical practice should therefore encourage weight management because data consistently show that overweight and obesity are associated with progressive disease and increased overall mortality from prostate cancer and other diseases, especially cardiovascular disease. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：217 / 225

页数：8

共 39 条

[1]

Doll R., Peto R., The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today, J Natl Cancer Inst, 66, pp. 1191-1308, (1981)

[2]

Chan JM, Gann PH, Giovannucci EL: Role of diet in prostate cancer development and progression, J Clin Oncol, 23, pp. 8152-8160, (2005)

[3]

Demark-Wahnefried W., Moyad M.A., Dietary intervention in the management of prostate cancer, Current Opin Urol, 17, pp. 168-174, (2007)

[4]

Fleshner N., Zlotta A.R., Prostate cancer prevention: Past, present, and future, Cancer, 110, pp. 1889-1899, (2007)

[5]

Shukla S., Gupta S., Dietary agents in the chemoprevention of prostate cancer, Nutr Cancer, 53, pp. 18-32, (2005)

[6]

Thompson I.M., Tangen C.M., Klein E.A., Lippman S.M., Phase III prostate cancer prevention trials: Are the costs justified?, J Clin Oncol, 23, pp. 8161-8164, (2005)

[7]

Canby-Hagino, Thompson IM: Mechanism of disease: prostate cancer - a model for cancer chemoprevention in clinical practice, Nature Clin Pract Oncol, 2, pp. 255-261, (2005)

[8]

Lamb D.J., Zhang L., Challenges in prostate cancer research: Animal models for nutritional studies of chemoprevention and disease progression, J Nutr, 135, 12, (2005)

[9]

Pryor W.A., Stahl W., Rock C.L., Beta carotene: From biochemistry to clinical trials, Nutr Rev, 58, pp. 39-53, (2000)

[10]

The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group: The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers, N Engl J M, 330, pp. 1029-1035, (1994)

← 1 2 3 4 →